
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics has demonstrated promising developments in its gene therapy candidate portfolio, particularly within the ophthalmology segment, where recent data from phase IIb trials indicate significant efficacy, with reductions of 94% and 92% in key measures through years one and one and a half, respectively. The company's strategic focus on one-time functional cures that offer safe, effective outcomes and lower system costs enhances its market position, alongside an improved benefit/risk profile for its lead candidates addressing wet AMD and diabetic macular edema. Additionally, 4D's strengthened cash position and collaboration with Otuska have increased the probability of success for advancing to phase III trials, underpinning a favorable outlook for investors.
Bears say
The financial outlook for 4D Molecular Therapeutics Inc is marked by significant uncertainties stemming from the potential underperformance of early trial results in later stages, which could lead to downward revisions in projected financial metrics. Additionally, the company faces challenges related to manufacturing capacity, which could materially constrain revenue forecasts and limit operational scalability. Coupled with the inherent risks associated with being a non-revenue generating entity, the stock's volatility could result in substantial swings that further complicate future financial projections.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares